The ethanolic lomustine formulation administered to male CD-1 mice as control in the pharmacokinetic studies was prepared as follows: 5 μl of polysorbate 80 was transferred into a glass vial containing 2 mg lomustine. The vial was vortexed for 1 minute and 895 μl of 5%
w/
v dextrose solution was added to it. The vial was vortexed for another 1 minute. It was then sonicated on ice for 30 minutes as described above. 100 μl of 10%
v/
v ethanol was added to the vial containing the lomustine, polysorbate 80 and 5%
w/
v dextrose solution and was vortexed for 1 minute. The content of the vial was filtered through a 0.22 μm
syringe filter (Millipore).
The ethanolic lomustine formulation administered as control in the pharmacodynamics and toxicity studies was prepared by vortexing lomustine (2 mg) in absolute ethanol (100 μl) with polysorbate 80 (5 mg ml
−1) in 5%
w/
v dextrose solution (final ethanol concentration of 10%
v/
v). The resulting colloidal mixture was then filtered (0.22 μm; Millipore
syringe filter) to remove drug crystals and yield a non-particulate formulation.
The lomustine content of the formulations was determined by HPLC analysis of the filtrate.
Fisusi F.A., Siew A., Chooi K.W., Okubanjo O., Garrett N., Lalatsa K., Serrano D., Summers I., Moger J., Stapleton P., Satchi-Fainaro R., Schätzlein A.G, & Uchegbu I.F. (2016). Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels – A Strategy for Brain Cancer Treatments. Pharmaceutical Research, 33, 1289-1303.